
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc has reported impressive financial growth, with record total revenues of $12.1 million for the quarter, marking a 154% year-over-year increase and surpassing consensus estimates. The company's strong quarterly performance is attributed to a higher average selling price driven by increased Medicare patient volume, alongside a 106% year-over-year rise in total revenue units. With a robust gross margin of 71% and a growing reimbursement pipeline of 1,389 units, Myomo is poised for continued revenue increases, projecting total revenue of $52.3 million in 2025, reflecting a significant upward revision from earlier estimates.
Bears say
Myomo Inc's financial outlook presents several challenges, notably a decrease in backlog for insurance-authorized orders, which declined from 316 to 272, indicating potential difficulties in future revenue generation. Additionally, the company faces significant risks related to its balance sheet and liquidity, regulatory approvals, competition, and reimbursement challenges, all of which could impede its ability to commercialize products effectively. Although Myomo reported a smaller net loss than expected at $0.01 per share as opposed to the consensus estimate of $0.02, the underlying risks and concerns overshadow growth prospects, contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares